TARGET: A Major European Project Aiming to Advance the Personalised Management of Atrial Fibrillation-Related Stroke via the Development of Health Virtual Twins Technology and Artificial Intelligence
Sandra Ortega-Martorell,Ivan Olier,Mattias Ohlsson,Gregory Y.H. Lip,on behalf of the TARGET Consortium
DOI: https://doi.org/10.1055/a-2438-5671
2024-11-09
Thrombosis and Haemostasis
Abstract:Atrial fibrillation (AF) is the most prevalent heart arrhythmia globally, resulting in severe complications, substantial financial costs, and significant resource use.[1] AF frequently goes unnoticed until the patient presents with AF-related complications (e.g., stroke, heart failure, dementia, and hospitalisations), particularly with brief episodes of AF that spontaneously revert to sinus rhythm. In Europe, stroke (a major complication of AF) is a leading cause of death and the top cause of disability. The pathophysiology of AF-related stroke (AFRS) involves severe neurological deficits, which considerably worsens prognosis. While risk factors for poor stroke outcomes are known, current AF prediction models have limitations and fail to account for dynamic changes in risk profiles.[2] [3] In addition, the importance of various stroke risk factors in AF may have changed over the years, for example, sex differences in AFRS risk.[4] [5] This has had implications for stroke risk stratification, concerning the use of the well-validated CHA 2 DS 2 -VASc score or a nonsex version (CHA 2 DS 2 -VA).[6] [7] [8] Nevertheless, recognizing the residual cardiovascular risks associated with AF despite anticoagulation, the management of this condition has moved toward a more holistic or integrated care approach, which has been associated with better clinical outcomes.[9] [10] This has led to such an approach recommended in contemporary guidelines.[11] [12] [13] [14] Stroke prevention is central to AF management.[15] Indeed, oral anticoagulant treatment in AFRS presents a dilemma: early initiation may increase haemorrhagic transformation risk, whereas delays can lead to recurrent ischaemic strokes. Poststroke rehabilitation, crucial for reducing risks and improving outcomes, lacks consensus on effective protocols, particularly personalised approaches based on functional outcomes in AFRS patients. This uncertainty can result in the exclusion of patients who would benefit from rehabilitation or the inefficient use of health care resources on those unlikely to help. Given this background, the European Union, through the Horizon Europe Research Program, has funded the "Health Virtual Twins for the Personalised Management of Stroke Related to Atrial Fibrillation" (TARGET) Project (grant agreement no. 101136244). TARGET's consortium involves 19 partners including universities, hospitals, companies, and a charity. The project kicked started in January 2024 under the scientific leadership of Prof. Sandra Ortega-Martorell (Principal Investigator, Liverpool John Moores University, LJMU), the methodological leadership in artificial intelligence (AI) and virtual twins of Prof. Ivan Olier (LJMU), the clinical leadership in AF and stroke of Prof. Gregory Lip (University of Liverpool), and the coordination of Prof. Mattias Ohlsson (Lund University). TARGET aims to address several clinical challenges within the AFRS disease pathway by focusing on a three-pillar approach: (Pillar I) Risk Prediction and dynamic, longitudinal monitoring of AF and the subsequent risk of developing AFRS; (Pillar II) Diagnosis and Management of AFRS, including early identification of stroke etiology, prediction of outcomes, and risk of stroke recurrence; and (Pillar III) Rehabilitation, focusing on identifying predictors of functional independence and quality of life in AFRS survivors and facilitating personalisation of rehabilitation. The project will be underpinned by the development of virtual twins of patients, which will be used to model novel, causal AI models embedded into decision-support tools for point-of-care applications. These novel models and tools will be evaluated via in silico simulated clinical trials and on newly collected data from clinical observational studies ([Fig. 1]). TARGET has a strong focus on the personalisation of health technologies for improved and more cost-efficient solutions in disease prevention, diagnosis, treatment and monitoring, better patient outcomes and well-being in the AFRS disease pathway, and reduced disease burden. TARGET will work closely with health care professionals (HCPs) and patients, who will be at the core of the research and the project, to codevelop the tools and ensure their acceptance and adoption. For Pillar I, one of the tools (Tool 1) will embed TARGET models to provide HCPs with personalised risk prediction scores along with the causal factors and help patients understand how modifiable factors, e.g., lifestyle changes, could impact risk (e.g., increase or decrease) over time (dynamic, longitudinal monitoring of risk). TARGET will also build on Isansys' (partner) Patient Status Engine (PSE) to integrate and evaluate personalised risk prediction models when monitoring patients. The PSE is an end-to-end medical device (CE Class IIa) and a config -Abstract Truncated-
peripheral vascular disease,hematology